ArticleCureus2026
Retroperitoneal and Pelvic Myeloid Sarcoma in a Patient With JAK2-Positive Polycythemia Vera: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myeloid sarcoma (MS) is a rare extramedullary tumor composed of immature myeloid cells that may occur in association with acute myeloid leukemia or other myeloid neoplasms. We report a 75-year-old woman with JAK2-positive polycythemia vera who presented with abdominal pain, distension, and anorexia. Imaging revealed a large retroperitoneal and pelvic mass causing hydronephrosis. Biopsy demonstrated immature mononuclear cells positive for CD33, CD43, CD117, CD68, and CD163, consistent with MS with monocytic differentiation. Other malignancies were excluded, and flow cytometry was non-diagnostic. This case highlights the diagnostic challenge of MS and underscores the importance of integrating imaging, histopathology, and immunophenotyping for accurate diagnosis. Early recognition is critical, as untreated MS can progress to acute leukemia. Clinicians should consider MS in patients with myeloproliferative neoplasms presenting with atypical masses to guide timely therapy and improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.